VISTA, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Flux Power Holdings, Inc. (“Flux Power”) (NASDAQ: FLUX), a leading developer of advanced lithium-ion energy storage solutions and software-driven electrification for commercial and industrial equipment, today announced the pricing of an underwritten public offering of 3,840,000 shares of its common stock at a public offering price of $2.50 per share, before underwriting discounts and commissions. In addition, Flux Power has granted the underwriter a 30-day op ...

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,025,000 shares of its common stock, at a public offering price of $12.9999 per pre-funded warrant, for a total ...

NexMetals Announces Upsizing of Public Offering to $80 MillionFurther Upsized from $65 Million Due to Strong DemandOctober 30, 2025 9:25 AM EDT | Source: NexMetals Mining Corp.Vancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - NexMetals Mining Corp. (TSXV: NEXM) (NASDAQ: NEXM) (the "Company" or "NEXM") is pleased to announce that it has increased the size of its previously announced "best efforts" public offering (the "Offering") of units of the Company ("Units") from up to C$6 ...

MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today the pricing of an underwritten public offering of (i) 1,400,000 shares of its common stock, (ii) pre-funded warrants to purchase up to 7,000,000 shares of its common stock, and (iii) accompanying Series A warrants to purchase up to 8,400,000 shares of common stock and a ...

公司融资活动 - 公司定价其承销的公开增发，发行7500万股普通股，每股面值0.125美元，预计总收益为9.64亿美元 [1] - 公司授予承销商30天期权，可额外购买最多1125万股普通股 [1] - 此次发行预计于2025年10月31日完成，需满足惯例交割条件 [1] - 公司拟将此次发行的净收益用于偿还其资产支持信贷额度下的借款，剩余部分用于一般公司用途 [2] 发行相关安排 - UBS Securities LLC担任此次发行的承销商，将通过纽约证券交易所、场外市场等多种方式销售普通股 [3] - 此次发行依据一份向美国证券交易委员会提交的新的自动生效储架注册声明进行 [4] - 初步招股说明书补充文件已提交美国证券交易委员会，最终文件可向UBS Securities LLC索取 [4] 公司业务概况 - 公司是北美领先的钢铁生产商，专注于增值板材产品，尤其服务于汽车行业 [6] - 公司业务垂直整合，涵盖铁矿石开采、球团矿和直接还原铁生产、废钢加工、初级炼钢以及下游精加工、冲压、模具和管材制造 [6] - 公司总部位于俄亥俄州克利夫兰，在美国和加拿大拥有约3万名员工 [6] - 根据补充信息，公司员工数为2.6万人，2021年营收为204亿美元，净收入为30亿美元 [11][16] 行业与技术动态 - 公司宣布在汽车冲压设备领域取得突破，成功完成生产试验，证明其钢材可在不更换昂贵模具的情况下替代铝材，用于关键汽车部件 [14] - 此次试验与一家主要汽车制造商合作进行，使用其现有铝成型设备冲压公司钢材部件，无缺陷产生 [14] 公司近期财务表现 - 公司报告2025年第三季度业绩，当期钢材发货量为400万净吨 [15] - 第三季度营收为47亿美元，GAAP净亏损为2.34亿美元，调整后净亏损为2.23亿美元，合每股稀释亏损0.45美元 [15] - 第三季度调整后EBITDA为1.43亿美元，截至2025年9月30日的流动性为31亿美元 [15]

Oct 27, 2025 11:30 PM Eastern Daylight Time VSE Corporation Prices Public Offering of Common Stock Share MIRAMAR, Fla.--(BUSINESS WIRE)--VSE Corporation ("VSE†or the "Company†) (NASDAQ: VSEC), a leading provider of aviation aftermarket distribution and repair services, announced today that it has priced its previously announced underwritten public offering. The Company is offering 2,352,941 shares of its common stock at a price to the public of $170.00 per share. VSE has also granted the underwriters a 30 ...

BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its previously announced underwritten public offering of 45,860,000 shares of its common stock at a public offering price per share of $2.90 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering price of $2.899 ...

公司融资活动 - RAPT Therapeutics公司宣布开始进行其普通股的承销公开发行[1] - 公司预计将授予承销商一项30天期权，允许其额外购买最多相当于本次发行普通股总数15%的股份[1] - 本次发行的所有普通股均由公司提供，发行取决于市场条件，最终能否完成、实际规模或条款均无法保证[1] 承销商信息 - 本次发行的联合账簿管理人为Leerink Partners、TD Cowen、Guggenheim Securities、Wells Fargo Securities和LifeSci Capital[2] - 本次发行的牵头管理人为H C Wainwright & Co 和 Clear Street[2] 发行法律依据 - 本次发行依据公司向美国证券交易委员会提交的货架注册声明进行，该声明已于2023年8月17日生效[3] - 发行只能通过招股说明书补充文件和随附的招股说明书进行，初步招股说明书补充文件将提交至美国证券交易委员会[3] 公司业务概况 - RAPT Therapeutics是一家临床阶段的、基于免疫学的生物制药公司，专注于为炎症和免疫性疾病患者发现、开发和商业化新型疗法[5] - 公司利用其在免疫学领域的深厚专业知识，开发旨在调节这些疾病关键免疫反应的新型疗法[5]

BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,025,480 shares of its common stock at a public offering price per share of $157.00 and, in lieu of shares of common stock, pre-funded warrants t ...

BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering will be offer ...